Acology’s Big First Quarter, Highlights of 10K in Letter to Shareholders

CORONA, Calif., April 17, 2017 -- A Letter from CEO Curt Fairbrother

Dear Shareholders:

I’m pleased to announce that as a result of late-year product additions, and continued surges of our signature product, Acology (OTC:ACOL) sales have significantly accelerated beyond our initial projections for the first quarter of 2017. Acology sold nearly half as many products in the first quarter as in all of 2016. This is attributable to gains in both national and global distribution, the addition of new distributors and expansion in the Canadian market. We believe that these trends will continue and that 2017 will be a banner year for us.

Friday’s publication of our 10K tracks the steady growth of our company from its inception and the success we’ve had in maintaining consistently high gross margins.  By its nature the financial report is very conservative. It is worth noting that double-digit increases in year-to-year sales have been remarkably consistent.  From 2013 to the present we have seen our business grow by an astonishing 770%. Our manufacturing arm is at less than 45% of capacity and poised for increased production. Our debt is manageable and the opportunity to significantly diminish it has already presented itself. We will update our progress in this endeavor as it develops.

We have always prided ourselves on growing the business from the inside-out, sometimes to the disappointment of our shareholders. We had the foresight to understand the emphasis and importance of multi-functional packaging in the medical and recreational cannabis industry. Increasing our sales force, although one of the largest of our expenditures, was the result of our commitment to become a global presence, especially in Canada. Most of our revenue is invested back into our business. We remain committed to these principles; steady growth, continued product diversity, concentrated person-to-person sales and marketing and the assurance of outstanding customer service.

Thank you for your continued trust and support. Acology is extremely confident that 2017 will be a breakout year. There is every indication, despite some uncertainty on the federal level, that our industry will continue to grow and prosper. We will continue with our commitment to position Acology as the premiere compliant-packaging solution at the head of that industry.

Curt Fairbrother, CEO

For investor or sales information please visit Acology Inc. and D&C Distributors online or by phone. The company is located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880.

Acology trades on the OTC under the call letters ACOL. The company’s websites are www.Acologyinc.com for the hospice and palliative care industry and www.themedtainer.com for the recreational and medical marijuana industry. Orders for Acology products can be taken online and by phone. Custom orders are especially welcome.  Please send all inquiries to [email protected] or call (844) ACOLOGY (844-226-5649). Ask for Jack Rein, National Services Director.  Acology can also be accessed through Twitter and Instagram at @Acologyinc

This press release includes statements that are covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events they are subject to risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the company’s current expectations. Forward-looking statements are identified by such words as “anticipates”, “projects”, “expects”, “planned”, “intends” and “believes” “estimate” “targets” and other similar expressions that indicate trends and future events. It is understood that investment entails risk on the part of the investor and could result in the loss of some or all his or her investment.